Executive Vice President and Chief Business Officer · Vir Biotechnology, Inc. (VIR)

Jeffrey Calcagno

FY2023 is the first fiscal year CompBrief holds for Jeffrey Calcagno as a named executive officer of Vir Biotechnology; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$4,540,126

Salary $314,394Stock awards $1,410,200Bonus $400,000

3rd of 9 named executive officers at Vir Biotechnology by FY2023 total.

9 named officers on file for Vir Biotechnology, FY2023

Jeffrey Calcagno’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • VIR’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vir Biotechnology’s whole pay program stands against its peers

  • Vir Biotechnology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VIR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 19, 2024 (DEF 14A).

Free

Get Jeffrey Calcagno’s full pay file as a PDF — free

More than this page: up to 10 years of Jeffrey’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jeffrey Calcagno compensation by year

Vir Biotechnology Summary Compensation Table · the one fiscal year held
In US dollars, as Vir Biotechnology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$314,394
Bonus$400,000
Stock awards$1,410,200
Option awards$2,269,432
Non-equity incentive$146,100
Pension and deferred compensation$0
All other$0
Total$4,540,126

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vir Biotechnology, Inc. DEF 14A filed April 19, 2024, accession 0001140361-24-020684, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vir Biotechnology, Inc. filed document, accession 0001140361-24-020684. Every figure is read from that document and cited to the page and table it appears in. Filed April 19, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU55,000$553,300—
Option110,000—$25.64

Per the Outstanding Equity Awards at Fiscal Year-End table in Vir Biotechnology, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Vir Biotechnology’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Marianne De BackerChief Executive Officer and Director$39,491,495
Sung LeeFormer Executive Vice President and Chief Financial Officer$4,848,374
Jeffrey Calcagno · this pageExecutive Vice President and Chief Business Officer$4,540,126
Johanna Friedl-NadererFormer Executive Vice President and Chief Operating Officer$4,395,064
Phillip PangFormer Executive Vice President, Chief Medical Officer and Interim Head of Research$3,952,190
Steven RiceFormer Executive Vice President and Chief Administrative Officer$3,260,800
Ann HanlyExecutive Vice President and Chief Technology Officer$3,113,931
Howard HornFormer Executive Vice President and Chief Financial Officer$601,300
George ScangosFormer President and Chief Executive Officer$338,200

The full Vir Biotechnology compensation record

free company brief

This page is one person within Vir Biotechnology's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vir Biotechnology proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vir Biotechnology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jeffrey Calcagno's compensation dossier · One-time report. No refunds.